Vice President, Ontario Pediatric Allergy Research Corporation Assistant Clinical Professor (Adjunct) in Pediatrics, McMaster University

**Business Address:** Halton Pediatric Allergy

5500 North Service Road, Suite 106, Burlington, Ontario, Canada L7L 6W6

Business Phone: 905-315-9543 — DocuSigned by Dr. Mariam Hanna

Business Facsimile: 905-592-2299

Dr. Mariam Hanna

I have reviewed this document 12/13/2022 | 7:09:08 PM PST

2002 - 2006

E-mail: mariam.hanna@medportal.ca

— CBF16EB02A5F4728B4BE28747DF0075B

Website: www.haltonpediatricallergy.com

#### **Current Employment & Positions**

| earrent Employment & rost                |   |                |
|--|---|----------------|
| Associate Investigator                   | Probity Medical Research, Pediatric Allergy, Asthma, and Immunology – Waterloo, Ontario | 2020 - Present |
| Sub-/Investigator                        | Halton Pediatric Allergy – Burlington, Ontario  | 2020 – Present |
| Vice President                           | Ontario Pediatric Allergy Research Corporation  – Burlington, Ontario                   | 2020 – Present |
| Co-Founder /<br>Pediatric Allergist      | Halton Pediatric Allergy, Private Practice – Burlington,<br>Ontario                     | 2017 – Present |
| Assistant Clinical Professor (Adjunct)   | Pediatrics, McMaster University – Hamilton, Ontario                                     | 2016 – Present |
| Degrees                                  |   |                |
| M.D. (with special training in research) | University of Alberta – Edmonton, Alberta   | 2006 – 2010    |

### **Post-Graduate Training**

B.Sc.

| Fellow   | Clinical Allergy and Immunology, McMaster University  – Hamilton, Ontario | 2013 – 2015 |
|----------|---|-------------|
| Resident | General Pediatrics, University of Alberta – Edmonton,                     | 2010 - 2013 |

Alberta

University of Alberta – Edmonton, Alberta

#### **Certification & Licensure**

| Royal College of Physicians and Surgeons of Canada, Clinical Immunology and | 2015 - Present |
|---|----------------|
| Allergy – Pediatric   |                |

Page 1 of 5 December 2022

| Royal College of Physicians and Surgeons of Canada, Pediatrics |  | 2014 – Present |  |  |
|--|--|----------------|--|--|
| College of Physicians and S                                    | 2015 – Present   |                |  |  |
| College of Physicians and S                                    | 2011, 2013 – 2015  |                |  |  |
| Licentiate Medical Council                                     | 2010   |                |  |  |
| Past Employment & Positions                                    |  |                |  |  |
| Pediatric Allergist  | Pediatric Allergy & Immunology, North Burlington<br>Medical Centre – Burlington, Ontario | 2016 – 2017    |  |  |
| Allergist (locum)  | Community Allergy & Immunology, Aviva Medical – Stoney Creek, Ontario                    | 2015 – 2016    |  |  |
| Faculty Disclosures  |  |                |  |  |
| MIRAVO   | Speaker  | 2022 – Present |  |  |
| TRUDELL  | Speaker  | 2019 – Present |  |  |
| Covis Pharmaceuticals  | Speaker  | 2019 – Present |  |  |
| ALK-Abello   | Advisory Board   | 2019 – Present |  |  |
| Pfizer Canada  | Speaker  | 2018 – Present |  |  |
| Stallergenes Canada  | Medical Consultant   | 2018 – Present |  |  |

#### **Research Activity & Clinical Trials**

- 1. 2021 An open-label, long-term extension study to evaluate the safety and efficacy of tapinarof cream 1% in subjects with atopic dermatitis (Sub-Investigator)
- 2021 A phase 3, multicenter, open-label extension study of the long-term safety of ARQ-151 Cream 0.15% and ARQ-151 cream 0.05% in subjects with atopic dermatitis (Principal Investigator)
- 3. 2021 A phase 3, 4-week, parallel group, double blind, vehicle-controlled study of the safety and efficacy of ARQ-151 cream 0.05% administered QD in subjects with atopic dermatitis (Principal Investigator)
- 4. 2021 A phase 3 efficacy and safety study of tapinarof for the treatment of moderate to severe atopic dermatitis in children and adults (Sub-Investigator)
- 5. 2021 A phase 2 study to evaluate the sensitivity, specificity and safety of DBV1605, a ready to use atopy patch test for the diagnosis of non-immunoglobulin e mediated cow's milk allergy in children (Sub-Investigator)

Page 2 of 5 December 2022

6. 2020 – A one-year placebo-controlled phase III trial evaluating the efficacy and safety of the house dust mite (HDM) SLIT-tablet in children (5-11 years of age) with HDM allergic rhinitis/rhinoconjunctivitis with or without asthma (Sub-Investigator)

#### **Clinical Trials Training**

Eczema Area and Severity Index (EASI)

Feb 2021

EASI – Body Surface Area (BSA) Severity Indices

SCORing Atopic Dermatitis (SCORAD)

SCORAD - BSA Serverity Indices - Objective Itch

Investigator Global Assessment (IGA) / Physician Global Assessment (PGA)

Protocol or training specified variations of EASI, SCORAD and IGA/PGA assessments

Kim Alexander Papp, MD, PhD, FRCPC – Visual and oral presentation with discussion and comment on methodology, standards, and consistency of assessment

Health Canada Division 5 - Drugs For Clinical Trials Involving Human Subjects Collaborative Institutional Training Initiative (CITI) – Web-base Training Course

Apr 2020

Good Clinical Practice (GCP) - Canada

Jan 2020

Collaborative Institutional Training Initiative (CITI) – Web-base Training Course

#### **Publications**

- 1. Mack DP, Greenhawt M, Turner PJ, Wasserman RL, <u>Hanna MA</u>, Shaker M, Hughes SW, Del Río PR. Information needs of patients considering oral immunotherapy for food allergy. Clin Exp Allergy 2022 Sep 9. [Epub ahead of print]. PMID: 36083693 / doi: 10.1111/cea.14225
- Chan ES, Jeimy S, <u>Hanna M</u>, Cook VE, Mack DP, Abrams EM, Soller L, Wong T, Protudjer JL. Caregiver views on virtual management of food allergy: A mixed-methods study. Pediatr Allergy Immunol 2021 Oct; 32(7): 1568-1572. Epub 2021 May 28. PMID: 33978254 / doi: 10.1111/pai.13539
- 3. Latrous M, Zhu R, Mack DP, Soller L, Chan ES, Jeimy S, <u>Hanna M</u>, Abrams EM, Cameron SB, Cook VE, Erdle S, Protudjer JLP, Wong T. Web-based Infant Food Introduction (WIFI): Feasibility and satisfaction of virtual allergist-supervised food introduction. J Allergy Clin Immunol Pract 2021 Sep; 9(9): 3521-3523.e1. Epub 2021 May 26. PMID: 34051393 / doi: 10.1016/j.jaip.2021.05.012
- 4. Mack DP, Soller L, Chan ES, <u>Hanna MA</u>, Terpstra C, Vander Leek TK, Bégin P. A High Proportion of Canadian Allergists Offer Oral Immunotherapy but Barriers Remain. J Allergy Clin Immunol Pract 2021 May; 9(5): 1902-1908. Epub 2020 Dec 29. PMID: 33359585 / doi: 10.1016/j.jaip.2020.12.025
- 5. Mack DP, Foster GA, Mack JD, Mack LC, <u>Hanna MA</u>. Weighing peanut candies used for oral immunotherapy mitigates variable peanut protein dose. J Allergy Clin Immunol Pract 2021 Jan; 9(1): 521-523.e1. Epub 2020 Aug 17. PMID: 32818698 / doi: 10.1016/j.jaip.2020.07.054
- Mack DP, Chan ES, Shaker M, Abrams EM, Wang J, Fleischer DM, <u>Hanna MA</u>, Greenhawt M. Novel Approaches to Food Allergy Management During COVID-19 Inspire Long-Term Change. J Allergy Clin Immunol Pract 2020 Oct; 8(9): 2851-2857. Epub 2020 Jul 25. PMID: 32721605 / doi: 10.1016/j.jaip.2020.07.020

- 7. Mack DP, Foster GA, Bouwers LM, <u>Hanna MA</u>. A counseling video with pre- and post- testing and checklist for oral immunotherapy consent improves participant knowledge. Ann Allergy Asthma Immunol 2020 Jul 7; doi: 10.1016/j.anai.2020.06.044
- 8. Mack DP, <u>Hanna MA</u>, Abrams EM, Wong T, Soller L, Erdle SC, Jeimy S, Protudjer JL, Chan ES, Virtually-supported home peanut introduction during COVID-19 for at-risk infants, J Allergy and Clin Immunol Pract 2020 Jun 10; S2213-2198(20)30589-4 [Epub ahead of print]. PMID: 32534149 / doi: 10.1016/j.jaip.2020.05.048
- 9. <u>Hanna</u>. Whatever Happened to Allergists? COVID 19 Hits Canada. Guest Editorial. AsthmaAllergiesChildren.org, 2020 Feb
- 10. **Hanna**. A Canadian Allergist's Tale of Two Eras. Guest Editorial. AsthmaAllergiesChildren.org, 2020 Feb

#### **Posters/Abstracts/Oral Presentations**

- 1. Mack DP, <u>Hanna M</u>. Web-based Infant Food Introduction (WIFI): Improving Access to Allergist-supervised Infant Food Introduction [Oral Presentation] American Academy of Allergy Asthma & Immunology Virtual Annual Meeting, Feb-Mar 2021.
- 2. Mack DP, <u>Hanna MA</u>. A real world evaluation of pediatric preschool peanut oral food challenges in a private practice clinic prior to oral immunotherapy. [Abstract/Oral Presentation] Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting, Montreal, Quebec, Oct 2019.
- 3. <u>Hanna MA</u>, Mack DP. An evaluation of logistical challenges associated with multi-food oral immunotherapy in a Canadian pediatric private practice clinic. [Abstract/Oral Presentation] Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting, Montreal, Ouebec, Oct 2019.
- 4. Mack DP, <u>Hanna MA</u>. The Use of a Counselling Video During an Oral Immunotherapy Counselling Session to Improve Parent and Patient Knowledge. [Abstract/Oral Presentation] Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting, Toronto, Ontario, Oct 2017.
- Mack DP, <u>Hanna MA</u>. Novel Suspension Medium for Peanut and Tree Nut Oral Immunotherapy -Canadian Pediatric Private Practice Oral Immunotherapy using NuT Suspension (Canadian -PPPOINTS). [Abstract/Oral Presentation] Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting, Toronto, Ontario, Oct 2017.
- 6. Mack DP, <u>Hanna MA</u>. The use of oral immunotherapy for milk allergy in a Canadian pediatric private practice clinic. [Abstract/Oral Presentation] Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting, Toronto, Ontario, Oct 2017.
- 7. <u>Hanna MA</u>, Mack DP. Inhaled Mometasone Furoate Induced Adrenal Suppression in an Adolescent. [Abstract/Oral Presentation] Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting, Ottawa, Ontario, Oct 2014.
- 8. <u>Hanna MA</u>, Mack DP. Use of Tiotropium Bromide in an Adolescent with Adrenal Suppression Secondary to Inhaled Mometasone Furoate. [Abstract/Oral Presentation] Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting, Ottawa, Ontario, Oct 2014.

Page 4 of 5 December 2022

### **Professional Memberships & Affiliations** Canadian Society of Allergy and Clinical Immunology, Pediatrics Section Chair 2022 - Present Ontario Medical Association, Chair, Section of Clinical Allergy & Immunology 2021 – Present Vice Chair, Section of Clinical Allergy & Immunology 2018 - 2021Ontario Medical Association, Member 2014 - Present Royal College of Physicians and Surgeons of Canada, Fellow 2014 - Present Canadian Society of Allergy and Clinical immunology, *Member* 2013 – Present American Association of Allergy, Asthma and Immunology, Member 2013 – Present Canadian Medical Association, Member 2012 - PresentCanadian Medical Protective Association, Member 2012 - Present

Page 5 of 5 December 2022